Veeva Systems (VEEV) Could Be 26% Undervalued After New AI And Data Wins
Veeva Systems (VEEV) is back in focus after highlighting how its Veeva DQS platform has processed data on more than 1 million clinical trial subjects across over 1,000 studies, along with new AI tools for configuring upcoming trials.
Recent product launches and new data wins appear to be feeding into sentiment around Veeva Systems, with a roughly 51% 90 day share price return and a 29% year to date share price gain, even as the 1 year total shareholder return has declined about 7%.
Scan beyond Veeva Systems and review other life sciences and healthcare software players pushing hard into AI by exploring our curated list of 34 healthcare AI stocks.
Veeva Systems has surged on real product traction in clinical data and life sciences software. The question now is whether that recent strength still leaves room for upside, or has pulled most of it forward into today’s price.
Most Popular Narrative: 26% Undervalued
Veeva Systems closed at $283.50, while the most followed narrative on the stock pegs fair value at $383.14 per share, implying a clear valuation gap that investors are watching closely.
Veeva appears to clear the first hurdle convincingly. The second depends on one’s assumptions about growth, AI monetization, competitive pressure, and required return.
See why 51 investors see Veeva Systems as 26% undervalued.
Result: Fair Value of $383.14 (UNDERVALUED)
Still, Veeva Systems faces pressure if pharmaceutical consolidation slows software decisions, or if Falcon adoption and pricing fall short of investor expectations.
Find out about the key risks to this Veeva Systems narrative.
Next Steps
Sentiment around Veeva Systems is clearly split, with investors weighing both upside drivers and meaningful pressure points, so move quickly, review the underlying data, and then shape your own view by checking the balance of 3 key rewards and 1 important warning sign.
Looking for more ideas beyond Veeva Systems?
If you want a broader view than Veeva Systems alone, use the Simply Wall Street Screener to surface fresh opportunities that match how you like to invest.
- Target higher potential upside by scanning a focused group of 19 high quality undiscovered gems that combine solid fundamentals with room for greater market attention.
- Prioritize durability and sleep-at-night resilience by zeroing in on 31 resilient stocks with low risk scores that score well on stability and financial strength.
- Anchor your watchlist around quality balance sheets by filtering for a list of solid balance sheet and fundamentals (25 results) that can better withstand shocks and funding pressures.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com